Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...
Colorectal cancer was found to be the most common malignancy and cause of death among patients with classic familial adenomatous polyposis.
Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback